X

Kopran Ltd. Stock Analysis

Small Cap
Evaluated by 693 users | BSE: 524280 | NSE: KOPRAN |
Pharmaceuticals & Drugs
The company was incorporated on April 26, 1958 as a private limited company under the name Kopran Chemical Company Pvt. Ltd. by Ramanlal V Shah Sevantilal, A Shah , Chimanlal G Sheth and Jivanalal M Shah. In 1972, the company’s management was acquired by Chemo Pharma Laboratories Ltd...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 4.42%5.05%9.1%10.65%6.21%8.4%3.92%1.83%6.49%5.74%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 192199250302326187182154197179
Y-o-Y Gr. Rt.-3.4%25.8%20.7%7.8%-42.5%-3.1%-15.3%27.9%-8.8%
Adjusted EPS (Rs.) 0.91.13.114.281.552.790.620.023.072.64
Y-o-Y Gr. Rt.-22.2%182.7%37.6%-63.8%80%-77.8%-96.8%15250%-14%
Book Value per Share (Rs.) 25.9427.5230.6134.9739.6443.4946.4647.5750.5153.11
Adjusted Net Profit 3.54.312.116.76.412.12.70.113.311.4
Net Op. Cash Flow (Rs. Cr.) 19.635.113.61.952.618.74.212.511.810
Debt to Cash Flow from Ops 5.552.927.5168.350.721.7813.394.174.224.58
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Kopran Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales -0.8%-11.3%-0.4%-8.8%
Adjusted EPS 12.7%11.2%62.1%-14%
Book Value per Share 8.364.65.2
Share Price 15.9% 10.2% 7.1% 171.2%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 3.293.799.9412.243.856.311.350.046.255.1
Operating Profit Margin (%) 9.6910.913.7114.119.7113.329.564.7211.7613.1
Net Profit Margin (%) 1.822.154.855.541.956.441.480.056.756.38
Debt to Equity 0.990.880.80.890.220.170.280.250.230.2
Working Capital Days 253265232228221267188233186229
Cash Conversion Cycle 3447375536225484283
Entity Percentage Holding
Promoters 43.78%
Institutions 2.41%
Non-Institutions 53.82%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Kopran's performance infers:

Kopran earnings have grown by 11.2%, whereas share price has appreciated 10.2% CAGR over the past five years, indicating the company's share price is likely undervalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Kopran share prices over the last 10 years. Here is what we found out:

Kopran share price has appreciated 7.4% annually over the past ten years.

The company was incorporated on April 26, 1958 as a private limited company under the name Kopran Chemical Company Pvt. Ltd. by Ramanlal V Shah Sevantilal, A Shah , Chimanlal G Sheth and Jivanalal M Shah. In 1972, the company’s management was acquired by Chemo Pharma Laboratories Ltd and the Company’s products were marketed by them.

Promoted by the Parijat Enterprises, Kopran is currently an integrated health care company. Kopran has used research-based technology to

The company was incorporated on April 26, 1958 as a private limited company under the name Kopran Chemical Company Pvt. Ltd. by Ramanlal V Shah Sevantilal, A Shah , Chimanlal G Sheth and Jivanalal M Shah. In 1972, the company’s management was acquired by Chemo Pharma Laboratories Ltd and the Company’s products were marketed by them.

Promoted by the Parijat Enterprises, Kopran is currently an integrated health care company. Kopran has used research-based technology to contribute towards total health-care. The company started modestly as a Semi Synthetic Penicillin (SSP) player and expanded to becomes the largest SSP Player in India with an annual SSP facility of over 1200 tones per annum.Subsequently the SSP business was hived off into a separate Company in a joint venture with Synpac Pharmaceuticals Ltd, UK.Kopran Laboratories Ltd. markets and supports high-tech life-saving medical equipments and diagnostics reagents since 1988.

Kopran Research Laboratories Ltd. (KRLL) is an emerging research organisation with particular interests in the areas of drug discovery, polymer technology and synthesis of new molecules.

Kopran is working towards creating and maintaining a global presence.Presence in Africa through Kampala Pharmaceutical Industries (KPI),a pharmaceutical company engaged in the manufacture and marketing of finished dosage forms in Uganda.

The company is having presence in the Middle East Market through a joint venture with Dubai Investment Corporation a leading investment company in Dubai for the manufacture and marketing of finished dosage forms in Dubai.

KRLL is a 100% subsidiary of Kopran Ltd.  KRLL is recognised by the Department of Science and Industrial Research (DSIR), Government of India. The company is staffed with competent and dedicated team of scientists.

Product range of the company includes:

Finished Dosage Forms

  • Antibiotics/antibacterials
  • Anti-malarial
  • Cadiovasculars
  • Pain management
  • Anthelminthics
  • Antiprotozoals
  • Antidiabetics
  • Gastrointestinals
  • Drug for erectile dysfuntion
  • Antiallergics
  • Respiratory/anti-asthmatics
  • Metered dose inhalers
  • Dry powder inhalers
  • Antiviral

Active Pharmaceutical Ingredients

  • Anti-hypertensives
  • Macrolides
  • Taste Masked
  • Cephalosporins 
  • Under Development
  • Others

Achievements/ recognition:

  • Kopran has a state of art manufacturing plants (Penicillin & General) approved by: -MCC (South Africa) -TGA, Australia and FDA, USA are in the pipeline

Future plans:

  • Brand Equity Development
  • Research for New Chemical Entities
  • Globalise its operations thus making Kopran a truly International Pharmaceutical Company.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback